Publications by authors named "Tyra Krause"

The recent expansion of mpox in Africa is characterized by a dramatic increase in zoonotic transmission (clade Ia) and the emergence of a new clade Ib that is transmitted from human-to-human (H2H) by close contact. Clade Ia does not pose a threat in areas without zoonotic reservoir. But clade Ib may spread widely, as did the clade IIb that since 2022 has spread globally among MSM.

View Article and Find Full Text PDF

Background: Despite evidence demonstrating that influenza vaccination is associated with reduced risk of cardiovascular events and all-cause mortality in individuals with diabetes mellitus (DM), vaccine uptake remains suboptimal.

Objectives: The purpose of this study was to assess the effectiveness of electronically delivered nudges on influenza vaccine uptake according to the presence of DM status versus other chronic diseases.

Methods: NUDGE-FLU-CHRONIC was a nationwide, randomized, pragmatic implementation trial among younger and middle-aged (18-64 years) Danish citizens with chronic disease during the 2023/2024 influenza season.

View Article and Find Full Text PDF

Objectives: The Bacillus Calmette-Guérin (BCG) vaccine may induce non-specific protection against unrelated infections. We tested the effect of BCG on the risk of infections among Danish senior citizens.

Methods: Single-blinded randomised controlled trial including 1676 volunteers >65 years.

View Article and Find Full Text PDF
Article Synopsis
  • Despite strong guidelines, flu vaccination rates are low among young and middle-aged people with chronic illnesses, indicating a need for effective strategies to boost these rates.
  • A nationwide clinical trial in Denmark tested whether sending behaviorally informed electronic letters could increase flu vaccination uptake in patients aged 18 to 64 with chronic diseases.
  • Results showed that patients who received any intervention letters had a higher vaccination rate (39.6%) compared to those who received usual care (27.9%), with the most significant impact coming from a follow-up letter sent 10 days later.
View Article and Find Full Text PDF
Article Synopsis
  • Digital letter interventions effectively increased influenza vaccination rates among Danish citizens aged 65 and older during the 2023-2024 flu season through a randomized trial.
  • Participants were divided into groups receiving usual care or various behaviorally informed electronic nudges before vaccination, revealing higher rates of vaccination in the nudge group compared to usual care (76.32% vs. 76.02%).
  • The nudges helped particularly those who were unvaccinated in the previous season, with consistent effects observed across different years, highlighting their scalability and potential for future flu seasons.
View Article and Find Full Text PDF

Vast amounts of pathogen genomic, demographic and spatial data are transforming our understanding of SARS-CoV-2 emergence and spread. We examined the drivers of molecular evolution and spread of 291,791 SARS-CoV-2 genomes from Denmark in 2021. With a sequencing rate consistently exceeding 60%, and up to 80% of PCR-positive samples between March and November, the viral genome set is broadly whole-epidemic representative.

View Article and Find Full Text PDF

Background: By March, 2023, 54 countries, areas, and territories (hereafter CAT) in the WHO European Region had reported more than 2·2 million COVID-19-related deaths to the WHO Regional Office for Europe. Here, we estimated how many lives were directly saved by vaccinating adults in the WHO European Region from December, 2020, to March, 2023.

Methods: In this retrospective surveillance study, we estimated the number of lives directly saved by age group, vaccine dose, and circulating variant-of-concern (VOC) period, regionally and nationally, using weekly data on COVID-19 mortality and infection, COVID-19 vaccination uptake, and SARS-CoV-2 virus characterisations by lineage downloaded from The European Surveillance System on June 11, 2023, as well as vaccine effectiveness data from the literature.

View Article and Find Full Text PDF

Background: Observational studies of SARS-CoV-2 vaccine effectiveness are prone to confounding, which can be illustrated using negative control methods.

Methods: Nationwide population-based cohort study including two cohorts of Danish residents 60-90 years of age matched 1:1 on age and sex: A vaccinated and a non-vaccinated cohort, including 61052 SARS-CoV-2 vaccinated individuals between 1 March and 1 July 2021 and 61052 individuals not vaccinated preceding 1 July 2021. From these two cohorts, we constructed negative control cohorts of individuals diagnosed with SARS-CoV-2 infection or acute myocardial infarction, stroke, cancer, low energy fracture, or head-trauma.

View Article and Find Full Text PDF
Article Synopsis
  • The European Mortality Monitoring Network (EuroMOMO) noticed more people are dying than usual since late November 2023.
  • In the early weeks of 2024, there were about 95 extra deaths for every 100,000 people in Europe, mostly affecting adults aged 45 and older.
  • This rise in deaths seems to be happening because of a lot of illnesses like COVID-19, flu, and RSV during the winter season.
View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to evaluate the effectiveness of high-dose quadrivalent influenza vaccine (QIV-HD) compared to standard-dose (QIV-SD) based on diabetes status, specifically looking at outcomes like glycated hemoglobin change (∆HbA1c), incident diabetes, and hospitalization rates.
  • - Conducted as a randomized trial among adults aged 65-79, results showed QIV-HD significantly reduced all-cause hospitalizations and was linked to lower risk of hospitalization and death related to pneumonia/influenza among those with diabetes, but did not significantly impact change in HbA1c or incident diabetes risk.
  • - Overall, QIV-HD demonstrated increased relative vaccine effectiveness against various health complications when compared to QIV-S
View Article and Find Full Text PDF

Background: In the NUDGE-FLU (Nationwide Utilization of Danish Government Electronic letter system for increasing inFLUenza vaccine uptake) trial, electronic letters incorporating cardiovascular (CV) gain-framing and repeated messaging increased influenza vaccination by approximately 1 percentage point.

Objective: To evaluate the effects of the successful nudging interventions on downstream clinical outcomes.

Design: Prespecified exploratory analysis of a nationwide randomized implementation trial.

View Article and Find Full Text PDF

Background: Yearly influenza vaccination is strongly recommended for older adults and patients with chronic diseases including cardiovascular disease (CVD); however, vaccination rates remain suboptimal, particularly among younger patients. Electronic letters incorporating behavioral nudges are highly scalable public health interventions which can potentially increase vaccination, but further research is needed to determine the most effective strategies and to assess effectiveness across different populations. The purpose of NUDGE-FLU-CHRONIC and NUDGE-FLU-2 are to evaluate the effectiveness of electronic nudges delivered via the Danish governmental electronic letter system in increasing influenza vaccination among patients with chronic diseases and older adults, respectively.

View Article and Find Full Text PDF

BACKGROUND: The relative vaccine effectiveness (rVE) of high-dose quadrivalent influenza vaccines (QIV-HD) versus standard-dose quadrivalent influenza vaccines (QIV-SD) against hospitalizations and mortality in the general older population has not been evaluated in an individually randomized trial. Because of the large sample size required, such a trial will need to incorporate innovative, pragmatic elements. METHODS: We conducted a pragmatic, open-label, active-controlled, randomized feasibility trial in Danish citizens aged 65 to 79 years during the 2021–2022 influenza season.

View Article and Find Full Text PDF

Objectives: To evaluate the relative effectiveness of high-dose quadrivalent influenza vaccine (QIV-HD) versus standard-dose quadrivalent influenza vaccine (QIV-SD) against recurrent hospitalizations and its potential variation in relation to influenza circulation.

Methods: We did a post-hoc analysis of a pragmatic, open-label, randomized trial of QIV-HD versus QIV-SD performed during the 2021-2022 influenza season among adults aged 65-79 years. Participants were enrolled in October 2021-November, 2021 and followed for outcomes from 14 days postvaccination until 31 May, 2022.

View Article and Find Full Text PDF

Importance: Influenza vaccination is associated with a reduced risk of mortality in patients with diabetes, but vaccination rates remain suboptimal.

Objective: To assess the effect of electronic nudges on influenza vaccination uptake according to diabetes status.

Design, Setting, And Participants: The NUDGE-FLU (Nationwide Utilization of Danish Government Electronic Letter System for Increasing Influenza Vaccine Uptake) trial was a nationwide clinical trial of Danish citizens 65 years or older that randomized participants at the household level to usual care or 9 different electronic nudge letters during the 2022 to 2023 influenza season.

View Article and Find Full Text PDF

Background: The BCG (Bacillus Calmette-Guérin) vaccine can induce nonspecific protection against unrelated infections. We aimed to test the effect of BCG on absenteeism and health of Danish health care workers (HCWs) during the coronavirus disease 2019 (COVID-19) pandemic.

Methods: A single-blinded randomized controlled trial included 1221 HCWs from 9 Danish hospitals.

View Article and Find Full Text PDF
Article Synopsis
  • A study in Denmark identified 10 cases of the SARS-CoV-2 variant BA.2.86, showcasing its genetic characteristics and presence in low levels through wastewater analysis.
  • The World Health Organization classified BA.2.86 as a variant under monitoring on August 17, 2023, due to its numerous mutations in the spike gene.
  • There is an ongoing need for global monitoring of COVID-19 and its variants, including BA.2.86, to track their spread and impact.
View Article and Find Full Text PDF

Several SARS-CoV-2 variants that evolved during the COVID-19 pandemic have appeared to differ in severity, based on analyses of single-country datasets. With decreased testing and sequencing, international collaborative studies will become increasingly important for timely assessment of the severity of new variants. Therefore, a joint WHO Regional Office for Europe and ECDC working group was formed to produce and pilot a standardised study protocol to estimate relative case-severity of SARS-CoV-2 variants during periods when two variants were co-circulating.

View Article and Find Full Text PDF

Background: Continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outpaces monovalent vaccine cross-protection to new viral variants. Consequently, bivalent coronavirus disease 2019 (COVID-19) vaccines including Omicron antigens were developed. The contrasting immunogenicity of the bivalent vaccines and the impact of prior antigenic exposure on new immune imprinting remains to be clarified.

View Article and Find Full Text PDF

Aims: Seasonal influenza vaccination is strongly recommended in patients with heart failure (HF). The NUDGE-FLU trial recently found two electronic behavioural nudging letter strategies - a letter highlighting potential cardiovascular benefits of vaccination and a repeated letter at day 14 -effective in increasing influenza vaccination in Denmark. The aims of this pre-specified analysis was to further examine vaccination patterns and effects of these behavioural nudges in patients with HF including potential off-target effects on guideline-directed medical therapy (GDMT) use.

View Article and Find Full Text PDF

Background: Influenza vaccination rates remain suboptimal despite effectiveness in preventing influenza infection and related complications. We investigated whether behavioural nudges, delivered via a governmental electronic letter system, would increase influenza vaccination uptake among older adults in Denmark.

Methods: We did a nationwide, pragmatic, registry-based, cluster-randomised implementation trial during the 2022-23 influenza season in Denmark.

View Article and Find Full Text PDF

Background: Influenza vaccines have been demonstrated to effectively reduce the incidence of influenza infection and potentially associated risks of cardiovascular events in patients with cardiovascular disease (CVD). Despite strong guideline and public health endorsements, global influenza vaccination rates in patients with CVD are highly variable. This prespecified analysis of NUDGE-FLU (Nationwide Utilization of Danish Government Electronic Letter System for Increasing Influenza Vaccine Uptake) examined the effect of digital behavioral nudges on influenza vaccine uptake based on the presence of CVD.

View Article and Find Full Text PDF

Background: Annual influenza vaccination is widely recommended in older adults and other high-risk groups including patients with cardiovascular disease. The real-world effectiveness of influenza vaccination is limited by suboptimal uptake and effective strategies for increasing vaccination rates are therefore needed. The purpose of this trial is to investigate whether behavioral nudges digitally delivered via the Danish nationwide mandatory governmental electronic letter system can increase influenza vaccination uptake among older adults.

View Article and Find Full Text PDF